Terminated PHASE3 INTERVENTIONAL 2-arm NCT05398263

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SUNRISE)

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SUNRISE)

Sponsor: Amgen

Conditions Asthma

Interventions Placebo Tezepelumab

Updated 27 times since 2022 Last updated: Apr 8, 2025 Started: Aug 9, 2022 Primary completion: Mar 24, 2025 Completion: Mar 24, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety concerns.

Other terminated trials from Amgen

See all terminations from Amgen

Other Asthma trials with similar outcome

Browse all Asthma trials

This PHASE3 trial investigates Asthma and is currently terminated or withdrawn. Amgen leads this study, which shows 27 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

27 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
May 2025 — Sep 2025 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Feb 2025 — May 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3

▶ Show 22 earlier versions

Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Mar 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Ajmer, India , Ankara, Turkey (Türkiye) , Bang Kra So, Thailand , Bangkok, Thailand , Bialystok, Poland , Botucatu, Brazil , Brno, Czechia , Bursa, Turkey (Türkiye) , Bychawa, Poland and 43 more locations